Create an account

Already have an account?
Technical support
Send
The password is: uppercase and lowercase English letters and numbers, no less than 6 characters
Submit

Login

Don’t have an account? Sign up
Forgot password?
Login
The assay is tailored to detect prevalent mutations in 10 genes: EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET, in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), using FFPE or Liquid Biopsy samples. Test outcomes are provided for clinical reference exclusively. Clinicians should evaluate the results in conjunction with the patient's medical status, drug indications, treatment response, and other laboratory test findings comprehensively.

Mutations( Hover over each mutational type to highlight genes covered )

All
CNV
FUSIONS
SNV/INDELS
EGFR

EGFR

SNV/INDELS
ALK

ALK

FUSIONS
SNV/INDELS
ROS1

ROS1

FUSIONS
SNV/INDELS
RET

RET

FUSIONS
SNV/INDELS
KRAS

KRAS

SNV/INDELS
NRAS

NRAS

SNV/INDELS
PIK3CA

PIK3CA

SNV/INDELS
BRAF

BRAF

SNV/INDELS
HER2

HER2

SNV/INDELS
MET

MET

CNV
SNV/INDELS

Fast turnaround time within 1 week

Fast turnaround time within
1 week

Automatic and secure data analysis

Automatic and secure data analysis

Target 10 driver genes for NSCLC/CRC

Target 10 driver genes for NSCLC/CRC

Detection of SNV, InDel, fusion, CNV

Detection of SNV, InDel, fusion, CNV

Specifications

Sample type
FFPE, the whole blood
Alterations detected
SNV, Indel, Fusion, CNV
DNA input
FFPE: optimal 100 ng
cfDNA: ≥10 ng (optimal 30 ng)

Publications

1. Yang, James Chih-Hsin et al. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. Journal of Thoracic Oncology, Volume 18, Issue 12, 1743 - 1755.

2. Ren, W.; Zhu, Y.; Wang, Q.; Jin, H.; Guo, Y.; Lin, D. Deep Learning-Based Classification and Targeted Gene Alteration Prediction from Pleural Effusion Cell Block Whole-Slide Images. Cancers 2023, 15, 752.

3. Qiu, D., Xi, H., Wang, M. et al. The debatable role of immune checkpoint blockade therapy in lung adenocarcinoma-oriented liver metastatic malignant lesions. J Cancer Res Clin Oncol 149, 5791–5802 (2023).

4. Cai, Y., Liu, H., Chen, X., Yang, J., & Huang, B. (2023). P40 and TTF‑1 double‑expressing non‑small cell lung cancer with EML4‑ALK and PIK3CA gene mutations: A case report and review of the literature. Oncology Letters, 25, 59.

5. Takamori S, Seto T, Yamaguchi M, Kinoshita F, Fujishita T, Ito K, Toyozawa R, Shoji F and Okamoto T (2022) Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation. Front. Oncol. 12:965741.

6. Ou, Sai-Hong Ignatius et al. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). Journal of Thoracic Oncology, Volume 17, Issue 12, 1404 - 1414.

7. Ma Y, Li Q, Du Y, Chen W, Zhao G, Liu X, Li H, Liu J, Shen Z, Ma L, Zhou Y. Oncogenic Genetic Alterations in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China. Cancer Manag Res. 2020;12:10861-10874.

8. Wu, W., Huang, Y., Guo, J., Xie, X., Li, H., Cao, Z., Wei, H. and Wu, C. (2020), Detection and comparison of EGFR mutations from supernatants that contain cell-free DNA and cell pellets from FNA non–small cell lung cancer specimens. Cancer Cytopathology, 128: 545-552.

9. Wu, W., Cao, Z., Zhang, W. et al. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients. Diagn Pathol 15, 9 (2020).

10. Xu H, Baidoo AA, Su S, Ye J, Chen C, Xie Y, Bertolaccini L, Ismail M, Ricciuti B, Ng CS, Flores RM, Li Y; written on behalf of AME Lung Cancer Collaborative Group. A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients. Transl Lung Cancer Res 2019;8(2):135-143.

11. Xiuhuan Ji, Nanying Che, Rixu lin, Jianou Chen, Xiuling Wu. Efficient ten-gene analysis of NSCLC tissue samples by next-generation sequencing. Pathology - Research and Practice, Volume 215, Issue 5, 2019, Pages 1066-1070.

Subscribe to our newsletter

Subscribe Now

Inquiry

Technical support
  • Technical support
  • Product Proposal
  • Information Consultant
  • Results Verification
  • Abnormal Results
  • Questioned Results
  • Other
Submit

Download

Don’t have an account? Sign up